Merck KGaA Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Belen Garijo Lopez

Chief executive officer

€10.5m

Total compensation

CEO salary percentage	14.2%
CEO tenure	9.8yrs
CEO ownership	n/a
Management average tenure	6.1yrs
Board average tenure	5.6yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Belen Garijo Lopez's remuneration changed compared to Merck KGaA's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2024	n/a	n/a	€3b
Jun 30 2024	n/a	n/a	€3b
Mar 31 2024	n/a	n/a	€3b
Dec 31 2023	€11m	€2m	€3b
Sep 30 2023	n/a	n/a	€3b
Jun 30 2023	n/a	n/a	€3b
Mar 31 2023	n/a	n/a	€3b
Dec 31 2022	€11m	€2m	€3b
Sep 30 2022	n/a	n/a	€3b
Jun 30 2022	n/a	n/a	€3b
Mar 31 2022	n/a	n/a	€3b
Dec 31 2021	€9m	€1m	€3b
Sep 30 2021	n/a	n/a	€3b
Jun 30 2021	n/a	n/a	€3b
Mar 31 2021	n/a	n/a	€2b
Dec 31 2020	€7m	€1m	€2b
Sep 30 2020	n/a	n/a	€2b
Jun 30 2020	n/a	n/a	€1b
Mar 31 2020	n/a	n/a	€2b
Dec 31 2019	€6m	€1m	€1b
Sep 30 2019	n/a	n/a	€1b
Jun 30 2019	n/a	n/a	€1b
Mar 31 2019	n/a	n/a	€938m
Dec 31 2018	€7m	€1m	€1b
Sep 30 2018	n/a	n/a	€2b
Jun 30 2018	n/a	n/a	€2b
Mar 31 2018	n/a	n/a	€2b
Dec 31 2017	€6m	€1m	€3b

Compensation vs Market: Belen's total compensation ($USD11.15M) is above average for companies of similar size in the MX market ($USD5.78M).

Compensation vs Earnings: Belen's compensation has been consistent with company performance over the past year.

CEO

Belen Garijo Lopez (64 yo)

9.8yrs

Tenure

€10,527,000

Compensation

Ms. Belen Garijo Lopez, M.D., is Chair of Executive Board and Chief Executive Officer of MERCK Kommanditgesellschaft auf Aktien since May 01, 2021. She served as Vice Chairman of the Executive Board and De...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Belen Garijo Lopez	Chair of Executive Board & CEO	9.8yrs	€10.53m	no data
Helene von Roeder	CFO & Member of Executive Board	1.3yrs	€1.23m	no data
Kai Beckmann	CEO of Electronics & Member of the Executive Board	13.6yrs	€8.26m	no data
Peter Guenter	CEO of Healthcare Business & Member of Executive Board	3.8yrs	€5.58m	no data
Matthias Heinzel	CEO of Life Science Sector & Member of Executive Board	3.6yrs	€5.22m	no data
Barbara Weiland	Chief Compliance Officer	5.3yrs	no data	no data
Dietmar Eidens	Head of the Global HR Business Partner Organization	9.8yrs	no data	no data
Frank Gotthardt	Head of Corporate & Government Relations - Europe	15.4yrs	no data	no data
Marc Horn	Head of Life Science Controlling	no data	no data	no data
Michael Heckmeier	Head of the Display Materials Business Unit for Performance Materials	7.6yrs	no data	no data
Hans-Joachim Neumann	Head of Integrated Supply Chain	6.1yrs	no data	no data
Tina Sandmann	Head of Internal Auditing	5.3yrs	no data	no data

6.1yrs

Average Tenure

57yo

Average Age

Experienced Management: MRK1 N's management team is seasoned and experienced (6.1 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Dietmar Oeter	Independent Member of Supervisory Board	10.5yrs	€50.80k	no data
Alexander Putz	Member of Supervisory Board	4.5yrs	€50.80k	no data
Stefan Palzer	Supervisory Board Member	less than a year	no data	no data
Barbara Lambert	Independent Member of Supervisory Board	1.3yrs	€30.50k	no data
Sascha Held	Vice Chair of Supervisory Board	5.6yrs	€89.30k	no data
Michael Kleinemeier	Independent Chairman of Supervisory Board	5.6yrs	€50.80k	no data
Anne Lange	Independent Member of Supervisory Board	5.6yrs	€50.80k	no data
Christian Raabe	Independent Member of Supervisory Board	5.6yrs	€65.80k	no data
Daniel Thelen	Independent Member of Supervisory Board	5.6yrs	€65.80k	no data
Simon Thelen	Independent Member of Supervisory Board	5.6yrs	€50.80k	no data
Birgit Biermann	Member of Supervisory Board	2.3yrs	€50.80k	no data
Katja Vila	Supervisory Board Member	less than a year	no data	no data

5.6yrs

Average Tenure

55yo

Average Age

Experienced Board: MRK1 N's board of directors are considered experienced (5.6 years average tenure).

Merck KGaA Management

Management criteria checks 3/4

Key information

Recent management updates

Merck KGaA, Annual General Meeting, Apr 25, 2025

Merck KGaA, Annual General Meeting, Apr 26, 2024

Merck Announces CFO Changes

Merck KGaA, Darmstadt, Germany, Announces Management Changes for North America and Global Innovative Medicine Franchises in Healthcare

Recent updates

Merck KGaA to Report Q4, 2024 Results on Mar 06, 2025

Merck KGaA Announces Phase III Maneuver Trial of Pimicotinib

Merck KGaA (XTRA:MRK) completed the acquisition of Unity Semiconductor SAS for €160 million.

Merck KGaA Announces First Patient Dosed in Phase III Study of Oral Cladribine in Generalized Myasthenia Gravis (gMG)

Merck KGaA (XTRA:MRK) intends to acquire Unity Semiconductor SAS.

Merck KGaA (XTRA:MRK) intends to acquire Unity Semiconductor SAS.

Merck KGaA Provides Update on Phase III TrilynX Study in Locally Advanced Head and Neck Cancer

Merck KGaA Provides Updates on the Oncology Pipeline and Focused Approach to the Research and Development of Potential New Medicines Designed to Improve the Futures of Cancer Treatment

Merck KGaA, Annual General Meeting, Apr 25, 2025

Daiichi Sankyo and Merck Announce That the First Patient Has Been Dosed in the Rejoice-Ovarian01 Phase 2/3 Trial Evaluating the Efficacy and Safety of Investigational Raludotatug Deruxtecan (R-DXd) in Patients with Platinum-Resistant Ovarian Cancer

Full year 2023 earnings released: EPS: €6.49 (vs €7.65 in FY 2022)

Merck Kgaa, Darmstadt, Germany Provides Update on Phase III Results for Evobrutinib in Relapsing Multiple Sclerosis

Merck Launches First Ever AI Solution to Integrate Drug Discovery and Synthesis

Merck KGaA to Report Q4, 2023 Results on Mar 07, 2024

Merck Receives Positive EU CHMP Opinion for PREVYMIS for Prevention of CMV Disease in High-Risk Adult Kidney Transplant Recipients and Extended 200-Day Dosing in Adult HSCT Recipients at Risk for Late CMV Infection and Disease

Merck KGaA, Annual General Meeting, Apr 26, 2024

Merck Announces CFO Changes

Merck Reportedly to Put Pigments Unit Up for Sale Again

MERCK Kommanditgesellschaft auf Aktien to Report Q4, 2022 Results on Mar 02, 2023

MERCK Kommanditgesellschaft auf Aktien Provides Earnings Guidance for the Full Year 2022

Gerresheimer and Merck Transform Primary Packaging into Digital Twins

Upcoming dividend of €1.85 per share

Now 21% undervalued after recent price drop

Now 22% undervalued

Full year 2021 earnings: Revenues in line with analyst expectations

MERCK Kommanditgesellschaft auf Aktien to Report Nine Months, 2022 Results on Nov 10, 2022

Third quarter 2021 earnings released

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Merck Launches New, High-Purity Synthetic Cholesterol Product

First quarter 2021 earnings released

Merck KGaA Provides Earnings Guidance for the First Quarter and Full Year of 2021

Merck KGaA Reports Topline Data for Bintrafusp Alfa as Second-Line Monotherapy Treatment in Biliary Tract Cancer

Genome and Company Signs Second Clinical Trial Collaboration and Supply Agreement (Phase 2) with Merck Kgaa, Darmstadt, Germany and Pfizer for Immuno-Oncology Microbiome Study

Full year 2020 earnings released: EPS €4.57 (vs €2.97 in FY 2019)

Revenue beats expectations

Merck Enters into Multiple Agreements to Support Efforts to Expand Manufacturing Capacity and Supply of SARS-CoV-2/COVID-19 Medicines and Vaccines

Merck and GPHL Collaborate on Business Innovation and Development in the Greater Bay Area

Day One Biopharmaceuticals Announces Global License Agreement with Merck KGaA, Darmstadt, Germany to Develop and Commercialize Mek Inhibitor Pimasertib

MERCK Kommanditgesellschaft auf Aktien to Report Q3, 2021 Results on Nov 11, 2021

4D Pharma plc Announces Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Germany and Pfizer to Evaluate MRx0518 in Combination with Bavencio for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma

Merck KGaA, Darmstadt, Germany, Announces Management Changes for North America and Global Innovative Medicine Franchises in Healthcare

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age